Drugs / FPV-CV301
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04574583 | Nov 2020 → Feb 2023 | metastatic malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03376659 | Aug 2018 → Aug 2021 | colorectal adenocarcinoma, metastasis from malignant tumor of colon, pancreatic adenocarcinoma | Georgetown University | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04491955 | Sep 2020 → Oct 2022 | colorectal cancer, small intestine cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT03628716 | Sep 2018 → Nov 2020 | urinary bladder cancer | Bavarian Nordic | Completed | No outcome recorded |
| Phase 2 | NCT03547999 | Jun 2018 → Mar 2024 | colorectal cancer | Patrick Boland | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FPV-CV301 | “Boost with FPV-CV301 (nominal titer of 1 × 10\^9 Inf.U in 0.5 mL, given SC every 21 days for 4 doses (on days 43, 64, 85, and 106), followed by boosts every 6 weeks until 6...” NCT03628716 ↗4“FPV-CV301 will be given as one subcutaneous injection (1x10\^9 Inf.U/0.5ml) on Day 1 starting at cycle 2 through cycle 5 (every 4 weeks) then on Day 1 of every 3 cycles (Cycles...” NCT04574583 ↗ “FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c.” NCT03376659 ↗ “CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301.” NCT04491955 ↗ |
| Modality | Vaccine | “followed by 4 vaccinations of FPV-CV301 given two weeks apart concurrently with mFOLFOX6 and Nivolumab” NCT03547999 ↗ |
| Route | Subcutaneous | “dosed at 1 × 109 Inf.U/0.5 mL given s.c.” NCT03376659 ↗ |